Factors Influencing Treatment Recommendations in Node-Negative Breast Cancer-Reference-Cited by-同舟云学术

Factors Influencing Treatment Recommendations in Node-Negative Breast Cancer

Published:2011-01 Issue:1 Volume:7 Page:26-30
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Elder Elisabeth Edstrom¹,Hay Sally Baron¹,Moore Katrina¹

Affiliation:

1. Royal North Shore Hospital, Sydney, Australia

Abstract

Grade, tumor size, estrogen-receptor status, and younger age are the most significant factors influencing adjuvant chemotherapy recommendation for patients with node-negative breast cancer.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.2010.000024

Reference15 articles.

1. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

3. Chemotherapy Use for Hormone Receptor–Positive, Lymph Node–Negative Breast Cancer

4. AJCC Cancer Staging Manual

5. Treatment Protocols, Breast Cancer Cancer Institute NSW http://www.eviq.org.au

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions;Journal of Clinical Oncology;2021-09-10

2. A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer;Internal Medicine Journal;2016-06

3. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer;Journal of Clinical Oncology;2016-01-10

4. Increasing rates of surgical treatment and preventing comorbidities may increase breast cancer survival for Aboriginal women;BMC Cancer;2014-03-07

5. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer;Genetics in Medicine;2013-03